Lifeward announces FDA clearance for ReWalk 7 exoskeleton

Lifeward (LFWD) has received 510(k) FDA clearance for the newest generation of its personal exoskeleton device, the ReWalk 7. The seventh generation of the ReWalk, a wearable exoskeleton that allows individuals with spinal cord injury to stand and walk again, includes a number of new features, as well as enhancements and upgrades. Clearance for the ReWalk 7 follows other major developments. In 2023, the FDA cleared the ReWalk 6.0 for use on stairs and curbs. In 2024, the Centers for Medicare & Medicaid Services issued a national reimbursement policy for all beneficiaries that qualify for use of the device. The Company made history in 2014 when it received the nation’s first FDA clearance for an exoskeleton medical device for individuals with SCI. Lifeward will begin sales of the ReWalk 7 in the United States as soon as the product is available